Abstract
The cancer burden continues to grow globally, exerting tremendous physical, emotional and financial strain on individuals, families, communities and health systems, immune dysfunction is an important cause of tumor development. A case -control study aimed to assess the role of IL-17 serum level in pathophysiology of lung cancer patients.150 patients attending to Middle Euphrates Cancer Center in AL-Najaf province from September till December 2021 that included 6(4%) small cell carcinoma patients and 144 (94 %) non small carcinoma patients from which squamous cell carcinoma patients represent 72(48%), Adenocarcenoma 48(16 %) and large –cell lung carcinoma 24(16%). as well as 30 apparently healthy subjects as control group . Two ml of vien blood were collected from all subjects put in gel tube to separate serum that used to estimate the IL-17 level by ELISA. The results showed a significant increase (P<0.05) in serum concentration of IL-17 in lung cancer patients compare to healthy subjects. According to stage of lung cancer the concentration of IL-17 increased with severity of disease and this considar as biomarker for prograssve of state.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
